This bill, titled the "Dietary Supplement Listing Act of 2026," amends the Federal Food, Drug, and Cosmetic Act to establish a mandatory listing requirement for all dietary supplements marketed in the United States. It requires the responsible person (manufacturer, packer, or distributor) to submit comprehensive information about each product to the Food and Drug Administration (FDA). Key information to be submitted includes the dietary supplement's name, the responsible person's contact details, an electronic copy of the product label, and a complete list of all ingredients, including amounts per serving. It also requires details on warnings, allergen statements, and any health claims made on the label. For foreign entities, a United States agent must be designated. Existing dietary supplements must be listed within 18 months of the act's enactment, while new supplements must be listed upon their introduction into interstate commerce. The FDA will assign a dietary supplement product listing number to each product and establish a publicly available electronic database containing most of the submitted information, excluding certain confidential business details like proprietary blend amounts. Failure to comply with these listing requirements will result in the dietary supplement being considered misbranded . The bill explicitly states that it does not grant the Secretary of Health and Human Services (via the FDA) the authority to require pre-market approval for dietary supplements. It also authorizes specific appropriations for the FDA to carry out these new responsibilities.